The FDA added a warning to the label of esketamine nasal spray (Spravato), noting that long-term cognitive and memory ...

One in five adults said they experienced any symptoms of anxiety or depression in a 2-week period, according to a 2022 CDC ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Esketamine nasal spray (Spravato) monotherapy was helpful in improving symptoms of treatment-resistant depression ...

The US drugs regulator has approved the sale of a new nasal spray to treat depression. Manufacturer Janssen says Esketamine can lift a patient's mood within 24 hours of use. The drug is intended ...

"This provides further evidence for the use of esketamine nasal spray in this difficult-to-treat population and offers hope for the millions of people affected by TRD," he added. Analysts at ...

An esketamine-based nasal spray antidepressant for adults is under review in the US following a filing from Johnson & Johnson's pharma unit. Janssen has submitted a filing for esketamine to the US ...

Approved in March 2019, esketamine is currently indicated for use alongside an oral antidepressant for treatment-resistant ...

Esketamine for TRD demonstrated efficacy in reducing depressive symptoms and did not significantly differ based on TMS treatment history.

When Dr. Husseini Manji was developing the first-in-class depression medication Spravato at Johnson & Johnson he encountered plenty of naysayers.

In April, she’d begun to use a topical nasal-spray decongestant. The over-the-counter (OTC) drug worked like a charm. By summer, she was still using the spray daily. Yet it was helping for ...

Learn more about how an anesthetic traditionally used for surgical procedures may help depression and what to expect during ...